XML 46 R20.htm IDEA: XBRL DOCUMENT v3.6.0.2
SEGMENT REPORTING
12 Months Ended
Dec. 31, 2016
Segment Reporting [Abstract]  
SEGMENT REPORTING
SEGMENT REPORTING
The Company is comprised of two reportable segments, Core Companion Animal Health ("CCA") and Other Vaccines, Pharmaceuticals and Products ("OVP"). The CCA segment includes diagnostic instruments and supplies, as well as single use diagnostic and other tests, pharmaceuticals and vaccines, primarily for canine and feline use. The CCA segment also includes digital radiography and ultrasound products along with embedded software and support, data hosting and other services from Heska Imaging. These products are sold directly by the Company as well as through independent third-party distributors and through other distribution relationships. CCA segment products manufactured at the Des Moines, Iowa production facility included in the OVP segment's assets are transferred at cost and are not recorded as revenue for the OVP segment. The OVP segment includes private label vaccine and pharmaceutical production, primarily for cattle, but also for other species including equine, porcine, avian, feline and canine. All OVP products are sold by third parties under third-party labels.

Summarized financial information concerning the Company's reportable segments is shown in the following table (in thousands):
Year Ended December 31, 2016
 
Core
Companion
Animal Health
 
Other Vaccines,
Pharmaceuticals
and Products
 
 
 
Total
Total revenue
 
$
107,398

 
$
22,685

 
$
130,083

Operating Income
 
13,015

 
3,518

 
16,533

Income before income taxes
 
12,938

 
3,566

 
16,504

Total assets
 
110,995

 
19,849

 
130,844

Net assets
 
68,072

 
18,903

 
86,975

Capital expenditures
 
1,135

 
2,282

 
3,417

Depreciation and amortization
 
3,800

 
845

 
4,645

Year Ended December 31, 2015
 
Core
Companion
Animal Health
 
Other Vaccines, Pharmaceuticals and Products
 
 
 
Total
Total revenue
 
$
84,249

 
$
20,348

 
$
104,597

Operating Income
 
4,911

 
3,646

 
8,557

Income before income taxes
 
4,836

 
3,591

 
8,427

Total assets
 
92,567

 
17,152

 
109,719

Net assets
 
48,175

 
15,353

 
63,528

Capital expenditures
 
1,177

 
2,596

 
3,773

Depreciation and amortization
 
3,478

 
709

 
4,187

Year Ended December 31, 2014
 
Core
Companion
Animal Health
 
Other Vaccines, Pharmaceuticals and Products
 
 
 
Total
Total revenue
 
$
72,354

 
$
17,483

 
$
89,837

Operating Income
 
1,198

 
1,713

 
2,911

Income before income taxes
 
1,290

 
1,660

 
2,950

Total assets
 
85,361

 
11,483

 
96,844

Net assets
 
41,286

 
11,846

 
53,132

Capital expenditures
 
1,864

 
473

 
2,337

Depreciation and amortization
 
2,954

 
758

 
3,712


Revenue is attributed to individual countries based on customer location. Total revenue by principal geographic area was as follows (in thousands):
 
For the Years Ended December 31,
 
2016
 
2015
 
2014
United States
$
120,082

 
$
97,164

 
$
83,584

Canada
2,378

 
1,833

 
1,123

Europe
4,781

 
2,086

 
2,264

Other International
2,842

 
3,514

 
2,866

Total
$
130,083

 
$
104,597

 
$
89,837


 
Total assets by principal geographic areas were as follows (in thousands):
 
For the Years Ended December 31,
 
2016
 
2015
 
2014
United States
$
127,827

 
$
106,780

 
$
93,977

Europe
3,017

 
2,939

 
2,867

Total
$
130,844

 
$
109,719

 
$
96,844